Article By:
Bio Deep Dives
Wednesday, May 24, 2023 9:55 AM EDT
IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology.
In this article: IKT
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
Bio Deep Dives, very thorough piece on #Inhibikase. But could you go into more depth about the competative landscape? Intersted in $IKT but wondering how the competition measures up.
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
Bullish on $IKT
Inhibikase Targets A Substantial Market Following Results Presented At The Barcelona Conference
Good analysis. Sounds like there's tremendous potential for $IKT!